title: PTV-based IMPT optimization incorporating planning risk volumes vs robust optimization.
abstract: OBJECTIVE
  Robust optimization leads to intensity-modulated proton therapy (IMPT) plans that are less sensitive to uncertainties and superior in terms of organs-at-risk (OARs) sparing, target dose coverage, and homogeneity compared to planning target volume (PTV)-based optimized plans. Robust optimization incorporates setup and range uncertainties, which implicitly adds margins to both targets and OARs and is also able to compensate for perturbations in dose distributions within targets and OARs caused by uncertainties. In contrast, the traditional PTV-based optimization considers only setup uncertainties and adds a margin only to targets but no margins to the OARs. It also ignores range uncertainty. The purpose of this work is to determine if robustly optimized plans are superior to PTV-based plans simply because the latter do not assign margins to OARs during optimization.
  
  
  METHODS
  The authors retrospectively selected from their institutional database five patients with head and neck (H&N) cancer and one with prostate cancer for this analysis. Using their original images and prescriptions, the authors created new IMPT plans using three methods: PTV-based optimization, optimization based on the PTV and planning risk volumes (PRVs) (i.e., "PTV+PRV-based optimization"), and robust optimization using the "worst-case" dose distribution. The PRVs were generated by uniformly expanding OARs by 3 mm for the H&N cases and 5 mm for the prostate case. The dose-volume histograms (DVHs) from the worst-case dose distributions were used to assess and compare plan quality. Families of DVHs for each uncertainty for all structures of interest were plotted along with the nominal DVHs. The width of the "bands" of DVHs was used to quantify the plan sensitivity to uncertainty.
  
  
  RESULTS
  Compared with conventional PTV-based and PTV+PRV-based planning, robust optimization led to a smaller bandwidth for the targets in the face of uncertainties {clinical target volume [CTV] bandwidth: 0.59 [robust], 3.53 [PTV+PRV], and 3.53 [PTV] Gy (RBE)}. It also resulted in higher doses to 95% of the CTV {D(95%): 60.8 [robust] vs 59.3 [PTV+PRV] vs 59.6 [PTV] Gy (RBE)}, smaller D(5%) (doses to 5% of the CTV) minus D(95%) {D(5%) - D(95%): 13.2 [robust] vs 17.5 [PTV+PRV] vs 17.2 [PTV] Gy (RBE)}. At the same time, the robust optimization method irradiated OARs less {maximum dose to 1 cm(3) of the brainstem: 48.3 [robust] vs 48.8 [PTV+PRV] vs 51.2 [PTV] Gy (RBE); mean dose to the oral cavity: 22.3 [robust] vs 22.9 [PTV+PRV] vs 26.1 [PTV] Gy (RBE); maximum dose to 1% of the normal brain: 66.0 [robust] vs 68.0 [PTV+PRV] vs 69.3 [PTV] Gy (RBE)}.
  
  
  CONCLUSIONS
  For H&N cases studied, OAR sparing in PTV+PRV-based optimization was inferior compared to robust optimization but was superior compared to PTV-based optimization; however, target dose robustness and homogeneity were comparable in the PTV+PRV-based and PTV-based optimizations. The same pattern held for the prostate case. The authors' data suggest that the superiority of robust optimization is not due simply to its inclusion of margins for OARs, but that this is due mainly to the ability of robust optimization to compensate for perturbations in dose distributions within target volumes and normal tissues caused by uncertainties.
authors: Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. wliu3@mdanderson.org
authors: Wei
authors: W
authors: Liu
authors: Steven J
authors: SJ
authors: Frank
authors: Xiaoqiang
authors: X
authors: Li
authors: Yupeng
authors: Y
authors: Li
authors: Ron X
authors: RX
authors: Zhu
authors: Radhe
authors: R
authors: Mohan
mesh_terms: D006258:Head and Neck Neoplasms / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D008297:Male; D058958:Organs at Risk / Q000528:radiation effects; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods*; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects / Q000379:methods*; D012208:Rhabdomyosarcoma / Q000473:pathology / Q000532:radiotherapy; D012306:Risk; D047368:Tumor Burden
references: Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):967-75
references: 9392533
references: Med Phys. 2009 Jan;36(1):149-63
references: 19235384
references: Pract Radiat Oncol. 2012 Jul-Sep;2(3):164-171
references: 22773939
references: Med Phys. 2012 Feb;39(2):1079-91
references: 22320818
references: Phys Med Biol. 2008 Mar 21;53(6):1689-700
references: 18367797
references: Radiother Oncol. 2012 Jul;104(1):45-51
references: 22560714
references: Radiother Oncol. 2002 Mar;62(3):299-307
references: 12175561
references: Med Phys. 2011 Mar;38(3):1672-84
references: 21520880
references: Z Med Phys. 2004;14(3):147-52
references: 15462415
references: Phys Med Biol. 2010 May 21;55(10):2863-78
references: 20427853
references: Radiother Oncol. 2006 Aug;80(2):263-7
references: 16916557
references: Med Phys. 2006 May;33(5):1510-21
references: 16752585
references: Med Phys. 2012 Jun;39(6):3089-101
references: 22755694
references: Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):589-96
references: 18793962
references: Phys Med Biol. 2008 Feb 21;53(4):1043-56
references: 18263957
references: Phys Med Biol. 2012 Feb 7;57(3):591-608
references: 22222720
references: Med Phys. 2001 Mar;28(3):317-24
references: 11318312
references: Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):428-34
references: 20100641
references: Phys Med Biol. 2008 Feb 21;53(4):1027-42
references: 18263956
references: Neurosurgery. 2004 Dec;55(6):1252-60; discussion 1260-2
references: 15574207
references: Phys Med Biol. 2007 May 21;52(10):2755-73
references: 17473350